Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes-MedSci.cn

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes

Planchard, D; Boyer, M; Lee, JS; Dechaphunkul, A; Cheema, P; Takahashi, T; Todd, A; McKeown, A; Rukazenkov, Y; Ohe, Y

ANNALS OF ONCOLOGY, 2018; 29 (): 169

科室
- - 订阅+
  - 更多科室
工具
服务